Kevin B Wilkins1, Matthew N Petrucci1, Yasmine Kehnemouyi1, Anca Velisar1,2, Katie Han1, Gerrit Orthlieb1, Megan H Trager1,3, Johanna J O'Day1,4, Sudeep Aditham1, Helen Bronte-Stewart1,5. 1. Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. 2. The Smith-Kettlewell Eye Research Institute, San Francisco, CA, USA. 3. Columbia University College of Physicians and Surgeons, New York City, NY, USA. 4. Department of Bioengineering, Stanford University, Stanford, CA, USA. 5. Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Abstract
BACKGROUND: Assessment of motor signs in Parkinson's disease (PD) requires an in-person examination. However, 50% of people with PD do not have access to a neurologist. Wearable sensors can provide remote measures of some motor signs but require continuous monitoring for several days. A major unmet need is reliable metrics of all cardinal motor signs, including rigidity, from a simple short active task that can be performed remotely or in the clinic. OBJECTIVE: Investigate whether thirty seconds of repetitive alternating finger tapping (RAFT) on a portable quantitative digitography (QDG) device, which measures amplitude and timing, produces reliable metrics of all cardinal motor signs in PD. METHODS: Ninety-six individuals with PD and forty-two healthy controls performed a thirty-second QDG-RAFT task and clinical motor assessment. Eighteen individuals were followed longitudinally with repeated assessments for an average of three years and up to six years. RESULTS: QDG-RAFT metrics showed differences between PD and controls and provided correlated metrics for total motor disability (MDS-UPDRS III) and for rigidity, bradykinesia, tremor, gait impairment, and freezing of gait (FOG). Additionally, QDG-RAFT tracked disease progression over several years off therapy and showed differences between akinetic-rigid and tremor-dominant phenotypes, as well as people with and without FOG. CONCLUSIONS: QDG is a reliable technology, which could be used in the clinic or remotely. This could improve access to care, allow complex remote disease management based on data received in real time, and accurate monitoring of disease progression over time in PD. QDG-RAFT also provides the comprehensive motor metrics needed for therapeutic trials.
BACKGROUND: Assessment of motor signs in Parkinson's disease (PD) requires an in-person examination. However, 50% of people with PD do not have access to a neurologist. Wearable sensors can provide remote measures of some motor signs but require continuous monitoring for several days. A major unmet need is reliable metrics of all cardinal motor signs, including rigidity, from a simple short active task that can be performed remotely or in the clinic. OBJECTIVE: Investigate whether thirty seconds of repetitive alternating finger tapping (RAFT) on a portable quantitative digitography (QDG) device, which measures amplitude and timing, produces reliable metrics of all cardinal motor signs in PD. METHODS: Ninety-six individuals with PD and forty-two healthy controls performed a thirty-second QDG-RAFT task and clinical motor assessment. Eighteen individuals were followed longitudinally with repeated assessments for an average of three years and up to six years. RESULTS: QDG-RAFT metrics showed differences between PD and controls and provided correlated metrics for total motor disability (MDS-UPDRS III) and for rigidity, bradykinesia, tremor, gait impairment, and freezing of gait (FOG). Additionally, QDG-RAFT tracked disease progression over several years off therapy and showed differences between akinetic-rigid and tremor-dominant phenotypes, as well as people with and without FOG. CONCLUSIONS: QDG is a reliable technology, which could be used in the clinic or remotely. This could improve access to care, allow complex remote disease management based on data received in real time, and accurate monitoring of disease progression over time in PD. QDG-RAFT also provides the comprehensive motor metrics needed for therapeutic trials.
Authors: Kaylena A Ehgoetz Martens; James M Shine; Courtney C Walton; Matthew J Georgiades; Moran Gilat; Julie M Hall; Alana J Muller; Jennifer Y Y Szeto; Simon J G Lewis Journal: Mov Disord Date: 2018-07 Impact factor: 10.338
Authors: Rob Powers; Maryam Etezadi-Amoli; Edith M Arnold; Sara Kianian; Irida Mance; Maxsim Gibiansky; Dan Trietsch; Alexander Singh Alvarado; James D Kretlow; Todd M Herrington; Salima Brillman; Nengchun Huang; Peter T Lin; Hung A Pham; Adeeti V Ullal Journal: Sci Transl Med Date: 2021-02-03 Impact factor: 17.956
Authors: Michele Matarazzo; Teresa Arroyo-Gallego; Paloma Montero; Verónica Puertas-Martín; Ian Butterworth; Carlos S Mendoza; María J Ledesma-Carbayo; María José Catalán; José Antonio Molina; Félix Bermejo-Pareja; Juan Carlos Martínez-Castrillo; Lydia López-Manzanares; Araceli Alonso-Cánovas; Jaime Herreros Rodríguez; Ignacio Obeso; Pablo Martínez-Martín; José Carlos Martínez-Ávila; Agustín Gómez de la Cámara; Martha Gray; José A Obeso; Luca Giancardo; Álvaro Sánchez-Ferro Journal: Mov Disord Date: 2019-06-18 Impact factor: 10.338
Authors: Michael T Barbe; Martin Amarell; Anke H Snijders; Esther Florin; Eva-Lotte Quatuor; Eckhard Schönau; Gereon R Fink; Bastiaan R Bloem; Lars Timmermann Journal: J Neurol Date: 2013-12-04 Impact factor: 4.849
Authors: L Giancardo; A Sánchez-Ferro; T Arroyo-Gallego; I Butterworth; C S Mendoza; P Montero; M Matarazzo; J A Obeso; M L Gray; R San José Estépar Journal: Sci Rep Date: 2016-10-05 Impact factor: 4.379
Authors: Elodie Múrias Lopes; Maria do Carmo Vilas-Boas; Duarte Dias; Maria José Rosas; Rui Vaz; João Paulo Silva Cunha Journal: Sensors (Basel) Date: 2020-01-07 Impact factor: 3.576
Authors: Larsson Omberg; Elias Chaibub Neto; Thanneer M Perumal; Abhishek Pratap; Aryton Tediarjo; Jamie Adams; Bastiaan R Bloem; Brian M Bot; Molly Elson; Samuel M Goldman; Michael R Kellen; Karl Kieburtz; Arno Klein; Max A Little; Ruth Schneider; Christine Suver; Christopher Tarolli; Caroline M Tanner; Andrew D Trister; John Wilbanks; E Ray Dorsey; Lara M Mangravite Journal: Nat Biotechnol Date: 2021-08-09 Impact factor: 54.908